Plasma ascorbate deficiency is associated with impaired reduction of sulfamethoxazole-nitroso in HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 5, 2004, Pages 1041-1050

  Trepanier, Lauren A ^a   Yoder, Andrea R ^a   Bajad, Sunil ^a   Beckwith, Michelle D ^b   Bellehumeur, Jennifer L ^b   Graziano, Frank M ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Detoxification; Hydroxylamine; Sulfonamide hypersensitivity; Vitamin C

Indexed keywords

ASCORBIC ACID; CYSTEINE; DEHYDROASCORBIC ACID; GLUTATHIONE; NITROSO DERIVATIVE; SULFAMETHOXAZOLE;

ADULT; ARTICLE; ASCORBIC ACID DEFICIENCY; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DETOXIFICATION; DRUG HYPERSENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REDUCTION; VITAMIN SUPPLEMENTATION;

ADULT; ANTI-INFECTIVE AGENTS; ASCORBIC ACID; ASCORBIC ACID DEFICIENCY; CASE-CONTROL STUDIES; CD4-CD8 RATIO; CYSTEINE; DEHYDROASCORBIC ACID; FEMALE; GLUTATHIONE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; SULFAMETHOXAZOLE;

EID: 3342989692     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200408150-00007     Document Type: Article

References (73)

1. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993;328:1521-1527.
2. Ioannidis J, Cappelleri J, Skolnik P, et al. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156:177-188.
3. Bucher H, Griffith L, Guyatt G, et al. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:104-114.
4. Ryan C, Madalon M, Wortham DW, et al. Sulfa hypersensitivity in patients with HIV infection: onset, treatment, critical review of the literature. Wis Med J. 1998;97:23-27.
5. DiRienzo A, vanDerHorst C, Finkelstein D, et al. Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. AIDS Res Hum Retroviruses. 2002;18:89-94.
6. Carr A, Cooper D. Pathogenesis and management of HIV-associated drug hypersensitivity. AIDS Clin Rev. 1995;6:65-97.
7. Lee B. Adverse reactions to trimethoprim-sulfamethoxazole. Clin Rev Allergy Immunol. 1996;14:451-455.
8. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990;323:776-782.
9. Kovacs J, Hiemenz J, Macher A, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome with other immunodeficiencies. Ann Intern Med. 1984;100:663-671.
10. Gordin FM, Simon GL, Wofsy CB, et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with AIDS. Ann Intern Med. 1984;100:495-499.
11. Walmsley SL, Khorasheh S, Singer J, et al. A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pneumocystis carinii pneumonia prophylaxis (CTN 057). J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:498-505.
12. Pertel P, Hirschtick R. Adverse reactions to dapsone in persons infected with human immunodeficiency virus. Clin Infect Dis. 1994;18:630-632.
13. Koch-Weser J, Sidel V, Dexter M, et al. Adverse reactions to sulfisoxazole, sulfamethoxazole, and nitrofurantoin. Manifestations and specific reaction rates during 2,118 courses of therapy. Arch Intern Med. 1971;128:399-404.
14. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis. 1982;4:426-428.
15. Naisbitt DJ, Hough SJ, Gill HJ, et al. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol. 1999;126:1393-1407.
16. Naisbitt D, Gordon S, Pirmohamed M, et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenization and T-cell proliferation in vivo. Br J Pharmacol. 2001;133:295-305.
17. Manchada T, Hess D, Dale L, et al. Haptenization of sulfonamide reactive metabolites to cellular proteins. Mol Pharmacol. 2002;62:1011-1026.
18. Naisbitt D, Farrell J, Gordon S, et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol Pharmacol. 2002;62:628-637.
19. Rieder MJ, Krause R, Bird IA. Time-course of toxicity of reactive sulfonamide metabolites. Toxicology. 1995;95:141-146.
20. Gill HJ, Hough SJ, Naisbitt DJ, et al. The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. J Pharmacol Exp Ther. 1997;282:795-801.
21. Shear NH, Spielberg SP, Grant DM, et al. Differences in metabolism of sulfonamides predisposes to idiosyncratic toxicity. Ann Intern Med. 1986;105:179-184.
22. Rieder MJ, Uetrecht J, Shear NH, et al. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med. 1989;110:286-289.
23. Carr A, Tindall B, Penny R, et al. In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV. Clin Exp Immunol. 1993;94:21-25.
24. Neuman M, Malkiewicz I, Phillips E, et al. Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individuals. Ther Drug Monit. 2002;24:728-736.
25. Carr A, Swanson C, Penny R, et al. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis. 1993;167;180-185.
26. Reilly TP, MacArthur RD, Farrough MJ, et al. Is hydroxylamine-induced cytotoxicity a valid marker for hypersensitivity reactions to sulfamethoxazole in human immunodeficiency virus-infected individuals? J Pharmacol Exp Ther. 1999;291:1356-1364.
27. Cribb AE, Miller M, Leeder JS, et al. Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione: implications for idiosyncratic toxicity. Drug Metab Dispos. 1991;19:900-906.
28. Naisbitt D, O'Neill P, Pirmohamed M, et al. Synthesis and reactions of nitroso sulphamethoxazole with biological nucleophiles: implications for immune mediated toxicity. Bioorg Med Chem Lett. 1996;6:1511-1516.
29. Cribb AE, Spielberg SP, Griffin GP. N4-Hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos. 1995;23:406-414.
30. Trepanier L, Miller J. NADH-dependent reduction of sulphamethoxazole hydroxylamine in dog and human liver microsomes. Xenobiotica. 2000;30:1111-1121.
31. Cribb AE, Spielberg SP. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther. 1992;51:522-526.
32. Cribb A, Miller M, Tesoro A, et al. Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs. Mol Pharmacol. 1990;38:744-751.
33. Treitinger A, Spada C, Verdi J, et al. Decreased antioxidant defence in individuals infected by the human immunodeficiency virus. Eur J Clin Invest. 2000;30:454-459.
34. Allard J, Aghdassi E, Chau J, et al. Oxidative stress and plasma micronutrients in humans with HIV infection. Am J Clin Nutr. 1998;67:143-147.
35. Lenton K, Therriault H, Cantin A, et al. Direct correlation of glutathione and ascorbate and their dependence on age and season in human lymphocytes. Am J Clin Nutr. 2000;71:1194-1200.
36. Naisbitt D, Vilar F, Stalford A, et al. Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection. AIDS Res Hum Refroviruses. 2000;16:1929-1918.
37. Lykkesfeldt J. Determination of ascorbic acid and dehydroascorbic acid in biological samples by high-performance liquid chromatography using subtraction methods: reliable reduction with tris[2-carboxyethyl]phosphine hydrochloride. Anal Biochem. 2000;282:89-93.
38. Jahoor F, Jackson A, Gazzard B, et al. Erythrocyte glutathione deficiency in symptom-free HIV infection is associated with decreased synthesis rate. Am J Physiol. 1999;276:E205-E211.
39. Stone I. Homo sapiens ascorbicus, a biochemically corrected robust human mutant. Med Hypotheses. 1979;5:711-721.
40. Lui C, Chen H, Lii C, et al. Alterations in plasma antioxidants and mitochondrial DNA mutation in hair follicles of smokers. Environ Mol Mutagen. 2002;40:168-174.
41. Lim P, Wang N, Lu T, et al. Evidence for alterations in circulating low-molecular-weight antioxidants and increased lipid peroxidation in smokers on hemodialysis. Nephron. 2001;88:127-133.
42. May J, Qu Z-C, Whitesell R, et al. Ascorbate recycling in human erythrocytes: role of GSH in reducing dehydroascorbate. Free Radic Biol Med. 1996;20:543-551.
43. Nakamura M, Ohtaki S. Formation and reduction of ascorbate radicals by hog thyroid microsomes. Arch Biochem Biophys. 1993;305:84-90.
44. Winkler B, Orselli S, Rex T. The redox couple between glutathione and ascorbic acid: a chemical and physiological perspective. Free Radic Biol Med. 1994;17:333-349.
45. Bogden J, Baker H, Frank O, et al. Micronutrient status and human immunodeficiency virus (HIV) infection. Ann N Y Acad Sci. 1990;587:189-195.
46. Nyyssonen K, Parviainen M, Salonen R, et al. Vitamin C deficiency and risk of myocardial infarction: prospective population study of men from eastern Finland. BMJ. 1997;314:634-638.
47. Uetrecht J. N-Oxidation of drugs associated with idiosyncratic drug reactions. Drug Metab Rev. 2002;34:651-665.
48. Dolle B, Topner W, Neumann H-G. Reaction of arylnitroso compounds with mercaptans. Xenobiotica. 1980;10:527-536.
49. Eyer P. Reactions of nitrosobenzene with reduced glutathione. Chem Biol Interact. 1979;24:227-239.
50. Buhl R, Holroyd KJ, Mastrangeli A, et al. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet. 1989;2:1294-1298.
51. Eck H-P, Gmunder H, Hartmann M, et al. Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1 infected patients. Biol Chem Hoppe Seyler. 1989;370:101-108.
52. Staal F, Ela S, Roederer M, et al. Glutathione deficiency and human immunodeficiency virus infection. Lancet. 1992;339:909-912.
53. Pirmohamed M, Williams D, Tingle MD, et al. Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency. AIDS. 1996;10:501-507.
54. Droge W. Cysteine and glutathione deficiency in AIDS patients: a rationale for the treatment with N-acetylcysteine. Pharmacology. 1993;46:61-65.
55. Aukrust P, Svardel A, Muller F, et al. Increased levels of oxidized glutathione in CD4+ lymphocytes associated with disturbed intracellular redox balance in HIV virus type 1 infection. Blood. 1995;86:258-267.
56. VanderVen AJAM, Mantel MA, Vree TB, et al. Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole. Br J Clin Pharmacol. 1994;38:147-150.
57. Allard J, Aghdassi E, Chau J, et al. Effect of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. AIDS. 1998;12:1653-1659.
58. Sauberlich H, Kretsch M, Taylor P, et al. Ascorbic acid and erythorbic acid metabolism in nonpregnant women. Am J Clin Nutr. 1989;50:1039-1049.
59. Duane W, Hutton S. Lack of effect of experimental ascorbic acid deficiency on bile acid metabolism, sterol balance, and biliary lipid composition in man. J Lipid Res. 1983;24:1186-1195.
60. Muller F, Svardal A, Nordoy I, et al. Virological and immunological effects of antioxidant treatment in patients with HIV infection. Eur J Clin Invest. 2000;30:905-914.
61. Harakeh S, Jariwalla R, Pauling L. Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells. Proc Natl Acad Sci U S A. 1990;87:7245-7249.
62. Harakeh S, Jariwalla R. Comparative study of the anti-HIV activities of ascorbate and thiol-containing reducing agents in chronically HIV-infected cells. Am J Clin Nutr. 1991;54:1231S-1235S.
63. Bowie A, O'Neill L. Vitamin C inhibits NF-kB activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol. 2000;165:7180-7188.
64. Bogden J, Kemp F, Han S, et al. Status of selected nutrients and progression of HIV type 1 infection. Am J Clin Nutr. 2000;72:809-815.
65. Lang C, Huang A, Ramirez J, et al. Erythrocytic glutathione and plasma cysteine status of human immunodeficient patients. Exp Biol Med. 2001;226:866-869.
66. Choi J, Liu R-M, Kundu R, et al. Molecular mechanism of decreased glutathione content in HIV type 1 Tat-transgenic mice. J Biol Chem. 2000;275:3693-3698.
67. May J, Qu Z-C, Whitesell R. Ascorbic acid recycling enhances the antioxidant reserve of human erythrocytes. Biochemistry (Mosc). 1995;34:12721-12728.
68. Guaiquil V, Farber C, Golde D, et al. Efficient transport and accumulation of vitamin C in HL-60 cells depleted of glutathione. J Biol Chem. 1997;272:9915-9921.
69. Martensson J, Meister A. Glutathione deficiency decreases tissue ascorbate levels in newborn rats: ascorbate spares glutathione and protects. Proc Natl Acad Sci U S A. 1991;88:4656-4660.
70. Johnston C, Meyer C, Srilakshmi J, Vitamin C elevates red blood cell glutathione in healthy adults. Am J Clin Nutr. 1993;58:103-105.
71. Jain A, Buist N, Kennaway N, et al. Effect of ascorbate or N-acetylcysteine treatment in a patient with hereditary glutathione synthetase deficiency. J Pediatr. 1994;124:229-233.
72. Pastore P, Rizzetto T, Curcuruto O, et al. Characterization of dehydroascorbic acid solutions by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom. 2001;15:2051-2057.
73. Deutsch J. Dehydroascorbic acid. J Chromatogr A. 2000;881:299-307.